Report Description Table of Contents Complement Inhibitors Market: How Are Rare Disease Treatments and Kidney Disease Approvals Expanding Commercial Opportunities? – (Updated On: 11th-Nov-2026) According to Strategic Market Research, the Global Complement Inhibitors Market was valued at USD 9.36 billion in 2025 and is projected to reach USD 18.68 billion by 2032, growing at a CAGR of 10.38%. These medicines help stop parts of the immune system from mistakenly damaging healthy blood cells, kidneys, nerves, or eyes. They treat conditions such as PNH, aHUS, myasthenia gravis, and certain kidney and eye diseases. The underlying patient population creates a defined treatment opportunity for complement inhibitors. Paroxysmal nocturnal hemoglobinuria (PNH) affects approximately 5,000 people in the United States. A 2025 U.S. claims study estimated its prevalence at 2.4 cases per 100,000 commercially insured people during 2018–2022. In the United Kingdom, the National PNH Service Annual Report 2024–2025 recorded 1,146 registered patients, of whom 439 were receiving complement inhibitor treatment, with another 17 receiving treatment through clinical trials or non-NHS-funded arrangements. These figures demonstrate an established patient population and continued demand for specialized treatments targeting complement-related blood cell destruction. Atypical hemolytic uremic syndrome (aHUS) is a rare disease in which the immune system mistakenly damages small blood vessels, particularly those in the kidneys. According to a 2025 Belgian study, 121 people had aHUS, representing approximately 10.4 patients per million residents. A separate 2025 European study examined 238 patients across 24 countries. Of these, 182 patients (76.5%) received complement inhibitor medicines, mainly eculizumab. These findings demonstrate actual treatment use and the need for medicines that prevent further blood vessel and kidney damage. Generalized myasthenia gravis (gMG) is another condition treated with complement inhibitors. According to Amgen, approximately 80,000–100,000 people in the United States have myasthenia gravis, and around 85% have the generalized form. Not all patients require complement inhibitors; these medicines are used for eligible patients with specific antibodies. A U.S. insurance study identified 27,968 patients with repeated diagnoses. Among them, 1,591 received selected biologic medicines, including 842 who received C5 inhibitors such as eculizumab and ravulizumab. This demonstrates actual treatment use in gMG. Neuromyelitis optica spectrum disorder (NMOSD) is a rare disease that can damage the eyes and spinal cord. A 2025 U.S. study estimated 7,175 patients, including 6,213 with the AQP4 antibody, which identifies patients who may qualify for certain complement inhibitor treatments (2025 study). These medicines block immune activity that can cause attacks. A 2026 international study followed 56 patients treated with eculizumab or ravulizumab (registry study). Disease complications create a need for effective complement inhibitor treatment. A 2025 U.S. study found that PNH patients taking C5 inhibitors required an average of 1.2 blood transfusions and experienced 4.5 episodes of red blood cell breakdown annually. In C3G, the FDA reports that approximately 50% of patients may develop kidney failure within 10 years. These complications increase the need for effective treatment. U.S. PNH Study | FDA Recent FDA approvals are creating more treatment options for patients with kidney diseases. In March 2025, the FDA approved Fabhalta for adults with C3G, a rare disease that can damage the kidneys. In July 2025, Empaveli was approved for C3G patients aged 12 and older. In July 2026, Fabhalta gained approval for certain adults with IgAN; its trial showed kidney function declined 48% more slowly than with placebo over two years. In October 2026, Ultomiris was approved to reduce proteinuria (excess protein in urine) in adults with IgAN. These specific medicines target proteins that can contribute to kidney damage in eligible patients. Several pharmaceutical companies are competing to develop medicines for different complement-related diseases. AstraZeneca sells Ultomiris and Soliris for conditions such as PNH, while Novartis offers Fabhalta, an oral medicine used for PNH and certain kidney diseases. Biogen markets Empaveli for blood and kidney disorders and Syfovre for geographic atrophy. Genentech offers Piasky for PNH, while UCB markets Zilbrysq for generalized myasthenia gravis. Companies compete through new disease approvals, easier treatment administration, longer dosing intervals, and improved patient outcomes. However, high treatment costs and biosimilar competition create pricing pressure. The Global Complement Inhibitors Market is projected to grow from USD 9.36 billion in 2025 to USD 18.68 billion by 2032. Demand comes from patients with rare blood, kidney, and neurological disorders. Treatment adoption is demonstrated by 182 European aHUS patients receiving C5 inhibitors, 842 U.S. gMG patients with C5 inhibitor claims in a selected treatment study, and 56 patients included in an NMOSD treatment registry. Commercially, the Ultomiris-related franchise generated USD 4.016 billion and Fabhalta generated USD 631 million during the first nine months of 2026. New approvals for kidney diseases are creating further treatment opportunities, although high medicine costs and limited patient access remain challenges. Which Complement Inhibitor Segments Lead the Market and Which Offer the Strongest Expansion Opportunities? Drug Class – C5 Inhibitors Lead Revenue, While Factor B Inhibitors Gain Commercial Momentum Leading Subsegment: C5 Inhibitors C5 inhibitors held a 62% share of the global Complement Inhibitors Market in 2025, valued at USD 5.803 billion, and are projected to grow at a CAGR of 8.60% during 2026–2032. C5 inhibitors prevent the breakdown of complement protein C5 into C5a and C5b, reducing harmful immune activity and tissue damage. Their established use in treating paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), and generalized myasthenia gravis contributes to their leading market position and continued clinical adoption. Fastest-Growing Subsegment: Factor B Inhibitors Factor B inhibitors accounted for 12% of the global Complement Inhibitors Market, valued at USD 1.123 billion in 2025, and are projected to register the fastest CAGR of 15.50% during 2026–2032. Factor B inhibitors selectively block the alternative complement pathway, helping control excessive immune activity while preserving other complement functions. Their targeted mechanism offers treatment opportunities for complement-mediated disorders, including paroxysmal nocturnal hemoglobinuria and certain kidney diseases. Increasing clinical adoption and expanding therapeutic applications are expected to strengthen their position in complement inhibitor treatment. Indication – PNH Remains the Largest Application, While Geographic Atrophy Opens a New Treatment Market Leading Subsegment: Paroxysmal Nocturnal Hemoglobinuria (PNH) Paroxysmal Nocturnal Hemoglobinuria (PNH) represents a major application within the Complement Inhibitors Market, accounting for approximately 38% of the global market, valued at USD 3.557 billion in 2025. The PNH application is projected to expand at a CAGR of 8.10% during 2026–2032. Complement inhibitors play an important role in managing PNH by preventing complement-mediated destruction of red blood cells. Increasing use of targeted C3 and C5 inhibitors, along with newer treatment options, is expected to strengthen their clinical adoption. Fastest-Growing Subsegment: Geographic Atrophy Geographic atrophy accounted for approximately 14% of the global Complement Inhibitors Market, valued at USD 1.310 billion in 2025, and is projected to register the fastest indication-level CAGR of 13.50% during 2026–2032. The condition involves progressive inflammation and tissue damage associated with complement system dysregulation, leading to deterioration of the retinal pigment epithelium (RPE), photoreceptors, and underlying choriocapillaris. Growing clinical adoption of complement inhibitors targeting C3 and C5 pathways is expanding treatment opportunities for slowing retinal degeneration and preserving visual function. Route of Administration – Intravenous Therapies Dominate, While Oral Formulations Improve Treatment Convenience Leading Subsegment: Intravenous Administration Intravenous (IV) administration remains the leading delivery route in the Complement Inhibitors Market, accounting for 67% of the global market, valued at USD 6.271 billion in 2025, with an anticipated CAGR of 8.90% during 2026–2032. IV administration is widely used for complement inhibitors treating rare immune-mediated disorders, including paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS). Established hospital infusion practices, controlled drug delivery, and the continued use of intravenous therapies such as eculizumab and ravulizumab support its leading market position. Fastest-Growing Subsegment: Oral Administration Oral administration accounted for a 12% market share, valued at USD 1.123 billion in 2025, and is projected to register the fastest growth among administration routes, with a CAGR of 16.70% during 2026–2032. The growing adoption of oral complement inhibitors reflects a shift from traditional intravenous and subcutaneous biologic therapies toward small-molecule treatments. Oral formulations offer greater convenience, reduce reliance on hospital-based infusions, and support long-term treatment adherence among patients with chronic complement-mediated disorders, including paroxysmal nocturnal hemoglobinuria. Distribution Channel – Specialty Pharmacies Maintain Leadership, While Retail Channels Offer Expansion Potential Leading Subsegment: Specialty Pharmacies Specialty pharmacies play a critical role in managing complement inhibitor therapies, particularly for patients with rare immune-mediated disorders requiring long-term treatment and continuous monitoring. In the global Complement Inhibitors Market, specialty pharmacies accounted for 48% of the market, valued at USD 4.493 billion in 2025, and are projected to grow at a CAGR of 10.10% during 2026–2032. Their involvement in coordinating treatment access, managing prescriptions, supporting medication adherence, and arranging specialized drug distribution strengthens their position in complement inhibitor therapy management. Fastest-Growing Subsegment: Retail Pharmacies Retail pharmacies accounted for a 15% market share, valued at USD 1.404 billion in 2025, and are projected to expand at a CAGR of 13.50% during 2026–2032. Retail pharmacies play an important role in providing access to prescribed complement inhibitor therapies for rare, severe, and chronic conditions such as paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), and generalized myasthenia gravis. The growing use of maintenance therapies and outpatient treatment is expected to strengthen pharmacy-based distribution. End User – Hospitals Remain the Primary Treatment Setting, While Ambulatory Infusion Centers Expand Their Role Leading Subsegment: Hospitals Hospitals play a central role in initiating, administering, and safely managing complement inhibitor therapies, particularly for patients with paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), and generalized myasthenia gravis. Hospitals accounted for 56% of the global Complement Inhibitors Market, valued at USD 5.242 billion in 2025, and are projected to expand at a CAGR of 9.50% during 2026–2032. Specialized infusion services, patient monitoring, infection-risk management, and ongoing treatment assessments strengthen hospitals' position as major providers of complement-targeted therapies. Fastest-Growing Subsegment: Ambulatory Infusion Centers Ambulatory Infusion Centers (AICs) play an important role in the Complement Inhibitors Market by providing specialized outpatient settings for administering intravenous (IV) and subcutaneous complement inhibitor therapies. In 2025, ambulatory infusion centers accounted for 13% of the global market, valued at USD 1.217 billion, with a projected CAGR of 12.20% during 2026–2032. Lower treatment costs compared with hospital-based infusion services, convenient appointment scheduling, and the growing preference for outpatient management of chronic complement-mediated disorders are supporting wider adoption of specialized infusion services. Geography – North America Leads Commercial Adoption, While Asia-Pacific Presents the Strongest Regional Opportunity Leading Subsegment: North America North America remains the leading region in the Complement Inhibitors Market, accounting for a 43% share and generating USD 4.025 billion in 2025, with a projected CAGR of 9.20% during 2026–2032. Clinical adoption has expanded beyond rare blood disorders into neurology, nephrology, and ophthalmology. Wider use of complement-targeted therapies for paroxysmal nocturnal hemoglobinuria (PNH), generalized myasthenia gravis, and geographic atrophy is strengthening the regional market. The United States remains a major contributor, supported by FDA-approved treatments, specialty healthcare infrastructure, and broader therapeutic applications. Fastest-Growing Subsegment: Asia-Pacific Asia-Pacific accounted for 22% of the Complement Inhibitors Market in 2025, equivalent to USD 2.059 billion. Japan, Australia, South Korea, and higher-income markets benefit from specialist-care capacity and established reimbursement pathways, while affordability and uneven healthcare access constrain uptake elsewhere. Asia-Pacific is projected to record the fastest regional growth, with a 13.30% CAGR from 2026 to 2032, supported by improved diagnosis and treatment access. Which Emerging Therapeutic Candidates Are Transforming the Complement Inhibitors Market? Zaltenibart (OMS906) – Novo Nordisk Zaltenibart is a monoclonal antibody targeting MASP-3, a protein involved in activating the alternative complement pathway. Originally developed by Omeros, the candidate was acquired by Novo Nordisk in 2025. It is being investigated for PNH and IgA nephropathy. Phase I and II studies in PNH have demonstrated clinical activity in treatment-naive patients and individuals with inadequate responses to existing C5 inhibitors. Novo Nordisk expects to initiate a Phase III PNH study in mid-2027. This program represents an opportunity to expand complement inhibition toward upstream pathway regulation. Empasiprubart (ARGX-117) – argenx Empasiprubart is an investigational monoclonal antibody targeting complement component C2. It is being evaluated for multifocal motor neuropathy (MMN) and chronic inflammatory demyelinating polyneuropathy (CIDP). The candidate has entered Phase III development in both indications. The Phase III EMPASSION study in MMN is expected to report results in December 2026, while the EMVIGORATE and EMNERGIZE studies in CIDP are expected to report results in the second half of 2027. Additional Phase II research is examining its potential in generalized myasthenia gravis. Claseprubart (DNTH103) – Dianthus Therapeutics Claseprubart is a selective antibody targeting activated C1s in the classical complement pathway. Its subcutaneous formulation is designed to support less frequent administration and potentially reduce dependence on infusion-based treatment. The candidate is undergoing Phase III trials for generalized myasthenia gravis and CIDP, with Phase II evaluation in MMN. An interim analysis of the first 40 participants completing the open-label portion of the CIDP study reported a 75% response rate. Phase III results in gMG are expected in the second half of 2028. Tanruprubart (ANX005) – Annexon Biosciences Tanruprubart is an intravenous monoclonal antibody designed to inhibit C1q and block activation of the classical complement pathway. Its principal development indication is Guillain-Barré syndrome (GBS), a neurological disorder involving immune-mediated nerve damage. In November 2026, Annexon reported that 18 patients had received treatment in its ongoing FORWARD study. The company expects to submit a U.S. Biologics License Application in the fourth quarter of 2026, while its European Marketing Authorisation Application is under review. Vonaprument (ANX007) – Annexon Biosciences Vonaprument is an investigational C1q inhibitor administered through intravitreal injection for geographic atrophy. The candidate is being evaluated in the Phase III ARCHER II trial. Its development focuses on protecting retinal function by reducing complement-mediated damage. The primary 15-month endpoint assessment is expected in the fourth quarter of 2026, followed by the 24-month assessment in 2027. CTx001 – Complement Therapeutics CTx001 is an investigational AAV gene therapy designed to deliver a mini-CR1 complement regulatory protein to the eye. It targets both classical and alternative complement pathway activity and is being developed for geographic atrophy. Its Phase I/II Opti-GAIN study progressed through two dosing cohorts in 2026. In September 2026, an independent monitoring committee recommended proceeding with higher-dose and expansion cohorts after reviewing the available safety data. Its single-administration approach could offer an alternative to treatments requiring repeated intravitreal injections. ARO-C3 and ARO-CFB – Arrowhead Pharmaceuticals These RNA interference (RNAi) candidates are designed to reduce the liver's production of complement proteins. ARO-C3 targets complement component C3, while ARO-CFB targets complement Factor B. Both programs are being investigated for complement-mediated diseases, particularly kidney disorders. Their development explores a different treatment approach from antibodies that directly bind circulating complement proteins. Both candidates are listed in early clinical development on Arrowhead's pipeline. CPV-104 – One04 Therapeutics CPV-104 is a recombinant human Factor H candidate designed to restore natural regulation of the complement system rather than directly suppressing an individual complement protein. Its development focuses on C3 glomerulopathy and other complement-mediated kidney diseases, with geographic atrophy also under consideration. Phase I research included 21 healthy volunteers in the single-ascending-dose portion and 18 patients across three multiple-ascending-dose cohorts. The company reported favorable initial safety and tolerability findings alongside early efficacy trends in C3G patients in September 2026. Phase II kidney-disease development and Phase I ophthalmic development are planned for early 2027. Pozelimab and Cemdisiran – Regeneron Pharmaceuticals This combination brings together pozelimab, a monoclonal antibody targeting C5, and cemdisiran, an RNAi therapy designed to reduce hepatic C5 production. The combination is being investigated for PNH and geographic atrophy. Its dual approach seeks to suppress terminal complement activity through both direct protein inhibition and reduced protein production. Regeneron continues to list the combination in its investigational pipeline Which Companies Are Strengthening Their Competitive Positions in the Complement Inhibitors Market? Alexion Pharmaceuticals (AstraZeneca) – Leading Company Alexion Pharmaceuticals, part of AstraZeneca's Rare Disease business, maintains a strong position through its established complement inhibitor portfolio, particularly Ultomiris (ravulizumab) and Soliris (eculizumab). Both medicines target the C5 protein and are used across multiple complement-mediated conditions, including PNH, aHUS, and generalized myasthenia gravis. Ultomiris has also received approval for neuromyelitis optica spectrum disorder (NMOSD) in several markets. According to AstraZeneca's 2025 annual reporting, Ultomiris generated USD 4.718 billion in revenue, increasing 20%, while Soliris generated USD 1.837 billion, although its revenue declined 29% as patients transitioned to Ultomiris and biosimilar competition increased. Ultomiris was approved in 73 countries for specified indications, demonstrating its extensive international commercial reach. The company is also advancing its portfolio through Voydeya (danicopan), an oral Factor D inhibitor used as an add-on treatment for certain PNH patients experiencing extravascular hemolysis. Competitive role: Alexion benefits from established physician relationships, broad international approvals, and a portfolio covering multiple rare diseases. Its strategy of moving patients toward longer-acting therapies while expanding complement inhibition into additional indications strengthens its position in the specialty biologics market. Novartis AG – Strong Position in Oral Complement Inhibitors Novartis has strengthened its competitive position through Fabhalta (iptacopan), an oral Factor B inhibitor that selectively targets the alternative complement pathway. Unlike conventional C5 inhibitors that are generally administered through infusions, Fabhalta provides an oral treatment option for patients with PNH and complement-mediated kidney disorders. Its regulatory expansion into C3 glomerulopathy and IgA nephropathy also provides access to additional patient populations. According to Novartis' full-year 2025 financial disclosures, Fabhalta generated USD 505 million in net sales, representing a 291% increase compared with 2024. The company attributed this performance to continued launch execution and market-share gains in PNH, alongside contributions from its renal indications. The FDA approved Fabhalta for PNH in December 2023 and C3G in March 2025. Competitive role: Novartis is positioning itself in the oral complement inhibitor segment. Its expansion across hematological and renal indications creates opportunities to compete beyond traditional intravenous C5 therapies and broaden its presence in specialist treatment markets. Other Important Companies and Their Market Roles: F. Hoffmann-La Roche Ltd: Commercializes PiaSky (crovalimab), a C5 inhibitor developed by Chugai Pharmaceutical. Its monthly subcutaneous maintenance administration provides an alternative to conventional intravenous C5 treatments for PNH. Regeneron Pharmaceuticals: Collaborates with Alnylam Pharmaceuticals on pozelimab and cemdisiran, combining direct C5 inhibition with RNA interference to reduce C5 production. The program is being investigated for complement-mediated conditions, including PNH. Sanofi: Commercializes Enjaymo (sutimlimab), a C1s inhibitor approved for hemolytic anemia in adults with cold agglutinin disease. It strengthens the company's presence in classical complement pathway inhibition Analyst Commentary: How Will Oral Therapies and Broader Approvals Shape Competitive Advantage? The competitive advantage in the complement inhibitors market will increasingly depend on developing oral therapies, improving dosing convenience, and targeting multiple complement pathways. Companies with clinically differentiated treatments and broader indication approvals are better positioned to capture specialist treatment opportunities and strengthen long-term patient retention. Complement Inhibitors Market Report Coverage Table Report Attribute Details Forecast Period 2026 – 2032 Market Size Value in 2025 USD 9.36 Billion Revenue Forecast in 2032 USD 18.68 Billion Overall Growth Rate CAGR of 10.38% (2026 – 2032) Base Year for Estimation 2025 Historical Data 2019 – 2024 Unit USD Million/Billion, CAGR (2026 – 2032) Segmentation By Drug Class, By Indication, By Route of Administration, By Distribution Channel, By End User, By Geography By Drug Class C5 Inhibitors, C3 Inhibitors, Factor B Inhibitors, Other Complement Inhibitors By Indication Paroxysmal Nocturnal Hemoglobinuria (PNH), Atypical Hemolytic Uremic Syndrome (aHUS), Generalized Myasthenia Gravis (gMG), Geographic Atrophy, C3 Glomerulopathy (C3G) and Other Renal Disorders, Other Indications By Route of Administration Intravenous Administration, Subcutaneous Administration, Oral Administration By Distribution Channel Specialty Pharmacies, Hospital Pharmacies, Retail Pharmacies By End User Hospitals, Specialty Clinics, Ambulatory Infusion Centers By Region North America, Europe, Asia-Pacific, Latin America, Middle East & Africa Country Scope U.S., Canada, UK, Germany, France, Italy, China, Japan, South Korea, India, Brazil, Mexico, Saudi Arabia, UAE, South Africa Market Drivers Established treatment use in PNH and aHUS, adoption among eligible gMG patients, and continued need to control complement-mediated disease complications Customization Option Available upon request Frequently Asked Question About This Report Q1. What factors are driving growth across the market? A1. Growth is supported by expanding treatment of PNH, aHUS, generalized myasthenia gravis, kidney diseases, and geographic atrophy, alongside new approvals and broader complement-targeted therapy options. Q2. Why are Factor B inhibitors gaining importance in the industry? A2. Factor B inhibitors are projected to record the fastest drug-class CAGR of 15.50% during 2026–2032. Their targeted action on the alternative complement pathway is creating opportunities across PNH and complement-mediated kidney diseases. Q3. Which route of administration offers the strongest growth opportunity in the market? A3. Oral administration is projected to record the fastest route CAGR of 16.70% during 2026–2032. Oral therapies can reduce dependence on infusion-based treatment and improve convenience for long-term patients. Q4. Which indication is creating the strongest expansion opportunity in the industry? A4. Geographic atrophy is projected to record the fastest indication CAGR of 13.50% during 2026–2032. Commercialization of complement-targeting ophthalmic treatments is expanding the market beyond traditional rare blood disorders. Q5. Which end-user segment is expected to expand the fastest? A5. Ambulatory infusion centers are projected to record the fastest end-user CAGR of 12.20% during 2026–2032. Greater outpatient administration of intravenous and subcutaneous therapies is supporting this shift. Q6. Which region is expected to record the fastest growth in the market? A6. Asia-Pacific is projected to record the fastest regional CAGR of 13.30% during 2026–2032. Growth is supported by improving diagnosis, expanding specialist healthcare capacity, and greater access to advanced complement therapies. Sources: NHS England-Commissioned National PNH Service – Reported 1,146 Patients in 2024–2025, Including 439 Receiving Complement Inhibitors and Another 24 Receiving Treatment Through Clinical Trials or Non-NHS-Funded Arrangements Across Leeds and King’s Centres National PNH Service – Annual Report 2024–2025: Patient Numbers and Complement Inhibitor Treatment U.S. FDA – Approved Fabhalta for Adults With C3 Glomerulopathy to Reduce Proteinuria in March 2025, With the Supporting Trial Showing a 35% Reduction in Urine Protein Compared With Placebo After Six Months FDA – First Approved Treatment for Adults With C3 Glomerulopathy U.S. FDA – Approved Empaveli on July 28, 2025, for C3 Glomerulopathy in Patients Aged 12 Years and Older to Reduce Proteinuria, With an August 20, 2026, Approval Extending the Indication to Reducing Kidney Function Loss FDA – Empaveli: C3 Glomerulopathy Approval Dates and Approved Indications Novartis – Announced Traditional FDA Approval of Fabhalta for Primary IgA Nephropathy on July 17, 2026, Following Trial Results Showing 48% Slower Kidney Function Decline Than Placebo Over Two Years Novartis – Fabhalta Traditional Approval for Slowing Kidney Function Decline in Primary IgAN AstraZeneca – Announced Accelerated U.S. Approval of Ultomiris for Reducing Proteinuria in Adults With Primary IgA Nephropathy on October 21, 2026, Based on a 43.4% Reduction Compared With Placebo at 34 Weeks AstraZeneca – Ultomiris Accelerated Approval for Primary IgA Nephropathy AstraZeneca – Reported USD 4.718 Billion in Ultomiris Revenue and USD 1.837 Billion in Soliris Revenue for 2025, With Ultomiris Growing 20% as Patient Demand and Switching From Soliris Expanded AstraZeneca – Annual Report 2025: Complement Inhibitor Revenue and Commercial Performance Novartis – Reported Fabhalta Net Sales of USD 505 Million in 2025, Representing 291% Growth Compared With 2024 Novartis – Full-Year 2025 Results: Fabhalta Sales and Therapeutic Expansion Novartis – Reported Fabhalta Net Sales of USD 631 Million During the First Nine Months of 2026, Including USD 237 Million in the Third Quarter Novartis – Third-Quarter 2026 Results: Fabhalta Commercial Performance Novartis Biogen – Completed Its Acquisition of Apellis Pharmaceuticals on May 14, 2026, Adding Empaveli and Syfovre, Which Together Generated USD 689 Million in Net Product Revenue During 2025 Biogen – Completion of Apellis Acquisition and Addition of Commercial Complement Inhibitors U.S. FDA – Approved PiaSky on June 20, 2024, for PNH in Adults and Patients Aged 13 Years and Older Weighing at Least 40 kg, Supported by the 204-Patient COMMODORE 2 Trial FDA – PiaSky Approval, Eligible Patient Population, and Supporting Clinical Trial UCB – Announced FDA Approval of Zilbrysq on October 17, 2023, for Adults With Generalized Myasthenia Gravis Who Are Anti-Acetylcholine Receptor Antibody Positive UCB – Zilbrysq Approval for Eligible Adults With Generalized Myasthenia Gravis UCB – Announced FDA Approval of a Zilbrysq Autoinjector on October 16, 2026, Expanding Self-Administration Options for Adults With Eligible Generalized Myasthenia Gravis UCB – Zilbrysq Autoinjector Approval and Self-Administration Development Novo Nordisk – Announced an Agreement With Omeros on October 15, 2025, for Global Development and Commercialization Rights to Zaltenibart, With Upfront and Near-Term Payments of USD 340 Million and Potential Total Payments of USD 2.1 Billion, Plus Royalties Novo Nordisk – Zaltenibart Acquisition and Licensing Agreement With Omeros Novo Nordisk – Its Third-Quarter 2026 Investor Presentation Identifies Mid-2027 as the Expected Start of a Phase III Zaltenibart Study in PNH, With Further Investigation in IgA Nephropathy Ongoing Novo Nordisk – Q3 2026 Presentation: Zaltenibart Development Plans argenx – Its October 22, 2026, Business Update Lists Empasiprubart in Phase III Development for MMN and CIDP, With MMN Results Expected in December 2026 and CIDP Results Expected in the Second Half of 2027 argenx – Q3 2026 Business Update: Empasiprubart Clinical Programs and Expected Milestones Dianthus Therapeutics – Reported a 75% Response Rate Among the First 40 Participants Completing the Open-Label Part A of Its Phase III CAPTIVATE Study of Claseprubart in CIDP Dianthus Therapeutics – Q3 2026 Update: Claseprubart Trial Results and Development Progress Annexon Biosciences – Its November 2026 Update Covers Tanruprubart Development for Guillain-Barré Syndrome and the Planned Fourth-Quarter 2026 Primary Endpoint Assessment for Vonaprument in the Phase III ARCHER II Geographic Atrophy Trial Annexon – Third-Quarter 2026 Results, Complement Inhibitor Programs, and Anticipated Milestones Complement Therapeutics – Announced Completion of Cohort 2 Dosing on September 1, 2026, With an Independent Monitoring Committee Recommending Progression to Higher-Dose and Expansion Cohorts in the Opti-GAIN Study of CTx001 for Geographic Atrophy Complement Therapeutics – CTx001 Opti-GAIN Phase I/II Clinical Development Update Arrowhead Pharmaceuticals – Lists ARO-C3 and ARO-CFB in Its Clinical Pipeline, Targeting Complement C3 and Factor B Production for Complement-Mediated Diseases Arrowhead Pharmaceuticals – Clinical Pipeline: ARO-C3 and ARO-CFB Programs One04 Therapeutics – Reported Interim CPV-104 Phase I Data on October 22, 2026, From a Study Including 21 Healthy Volunteers and Three Planned Multiple-Dose Cohorts Totaling 18 C3G Patients, With Early Safety and Biological Activity Findings Supporting Further Evaluation One04 Therapeutics – CPV-104 Phase I Interim Results in C3 Glomerulopathy Regeneron Pharmaceuticals – Lists Pozelimab Plus Cemdisiran in Its Investigational Pipeline for PNH and Geographic Atrophy, Supporting the Content’s Discussion of Combined Antibody and RNA Interference Approaches Regeneron – Investigational Pipeline: Pozelimab and Cemdisira Recordati – Completed Its Acquisition of Global Rights to Enjaymo From Sanofi on November 29, 2024; the Content’s Current Company Attribution Should Therefore Be Updated to Recordati Recordati – Acquisition of Global Rights to Enjaymo From Sanofi Table of Contents - Global Complement Inhibitors Market Report (2026–2032) Executive Summary Market Overview Market Attractiveness by Drug Class, Indication, Route of Administration, Distribution Channel, End User, and Region Strategic Insights from Key Executives (CXO Perspective) Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Summary of Market Segmentation by Drug Class, Indication, Route of Administration, Distribution Channel, End User, and Region Market Share Analysis Leading Players by Revenue and Market Share Market Share Analysis by Drug Class, Indication, Route of Administration, Distribution Channel, and End User Competitive Positioning of Established C5 Inhibitors and Emerging Complement-Targeted Therapies Investment Opportunities in the Complement Inhibitors Market Key Developments and Innovations Mergers, Acquisitions, and Strategic Partnerships High-Growth Segments for Investment Opportunities in C5 Inhibitors, C3 Inhibitors, Factor B Inhibitors, and Other Complement Inhibitors Investment Opportunities in PNH, aHUS, Generalized Myasthenia Gravis, Geographic Atrophy, C3 Glomerulopathy, and Other Renal Disorders Emerging Opportunities in Oral Complement Inhibitors, Subcutaneous Formulations, and Outpatient Infusion Services Pipeline Opportunities in MASP-3, C2, C1s, C1q, Factor H, and RNA Interference-Based Complement Therapies Market Introduction Definition and Scope of the Study Market Structure and Key Findings Overview of Top Investment Pockets Role of Complement Inhibition in Rare Blood, Kidney, Neurological, and Ophthalmic Diseases Therapeutic Importance of Complement Pathway Regulation in PNH, aHUS, gMG, NMOSD, Geographic Atrophy, and C3G Commercial Importance of Targeted Therapies, Oral Formulations, and Long-Acting Treatment Options Research Methodology Research Process Overview Primary and Secondary Research Approaches Market Size Estimation and Forecasting Techniques Data Triangulation and Segment-Level Forecasting Approach Historical Assessment (2019–2024), Base Year Evaluation (2025), and Forecast Analysis (2026–2032) Market Dynamics Key Market Drivers Challenges and Restraints Impacting Growth Emerging Opportunities for Stakeholders Impact of Regulatory Approvals and Healthcare Access Established Treatment Use in PNH and aHUS and Adoption Among Eligible gMG Patients Growing Demand for Complement Inhibitors in Kidney Disorders and Geographic Atrophy Impact of High Treatment Costs, Biosimilar Competition, and Patient Access Limitations Shift Toward Oral Therapies, Subcutaneous Administration, and Longer Dosing Intervals Impact of New Indication Approvals and Expanding Therapeutic Applications During 2025–2026 Global Complement Inhibitors Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Drug Class: C5 Inhibitors C3 Inhibitors Factor B Inhibitors Other Complement Inhibitors C1s Inhibitors Factor D Inhibitors C5a/C5aR Inhibitors MASP-Targeting Therapies Market Analysis by Indication: Paroxysmal Nocturnal Hemoglobinuria (PNH) Atypical Hemolytic Uremic Syndrome (aHUS) Generalized Myasthenia Gravis (gMG) Geographic Atrophy C3 Glomerulopathy (C3G) and Other Renal Disorders Other Indications Neuromyelitis Optica Spectrum Disorder (NMOSD) Cold Agglutinin Disease IgA Nephropathy (IgAN) Multifocal Motor Neuropathy (MMN) Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Guillain-Barré Syndrome (GBS) Market Analysis by Route of Administration: Intravenous Administration Subcutaneous Administration Oral Administration Market Analysis by Distribution Channel: Specialty Pharmacies Hospital Pharmacies Retail Pharmacies Market Analysis by End User: Hospitals Specialty Clinics Ambulatory Infusion Centers Market Analysis by Region: North America Europe Asia-Pacific Latin America Middle East & Africa Regional Market Analysis North America Complement Inhibitors Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Drug Class, Indication, Route of Administration, Distribution Channel, and End User Country-Level Breakdown: United States Canada Mexico Europe Complement Inhibitors Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Drug Class, Indication, Route of Administration, Distribution Channel, and End User Country-Level Breakdown: United Kingdom Germany France Italy Rest of Europe Asia-Pacific Complement Inhibitors Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Drug Class, Indication, Route of Administration, Distribution Channel, and End User Country-Level Breakdown: China Japan South Korea India Australia Rest of Asia-Pacific Latin America Complement Inhibitors Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Drug Class, Indication, Route of Administration, Distribution Channel, and End User Country-Level Breakdown: Brazil Mexico Rest of Latin America Middle East & Africa Complement Inhibitors Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Drug Class, Indication, Route of Administration, Distribution Channel, and End User Country-Level Breakdown: Saudi Arabia United Arab Emirates South Africa Rest of Middle East & Africa Competitive Intelligence and Benchmarking Leading Key Players: AstraZeneca plc (Alexion Pharmaceuticals) Novartis AG F. Hoffmann-La Roche Ltd Regeneron Pharmaceuticals, Inc. Sanofi S.A. Biogen Inc. UCB S.A. argenx SE Dianthus Therapeutics, Inc. Annexon, Inc. Novo Nordisk A/S Arrowhead Pharmaceuticals, Inc. One04 Therapeutics Complement Therapeutics Alnylam Pharmaceuticals, Inc. Omeros Corporation Competitive Landscape and Strategic Insights Benchmarking Based on Complement Pathway Targets, Therapeutic Portfolios, Clinical Evidence, Product Availability, and Regional Presence Supplier Qualification and Regulatory Compliance Capability Analysis C5 Inhibitor Portfolio Positioning and Long-Acting Therapy Strategies Oral Complement Inhibitor and Alternative Pathway Targeting Strategies Subcutaneous Formulation Development and Treatment Administration Differentiation Competitive Assessment of PNH, aHUS, gMG, Geographic Atrophy, and Renal Disease Treatments Pipeline Benchmarking Across MASP-3, C2, C1s, C1q, Factor H, and RNAi-Based Candidates Revenue and Product Performance Review for 2025 and 2026 Analyst Commentary Impact of Oral Therapies and Broader Indication Approvals on Competitive Advantage Commercial Outlook for Complement Inhibitors Across Rare Blood, Kidney, Neurological, and Ophthalmic Diseases (2026–2032) Role of Treatment Convenience, Dosing Intervals, and Patient Access in Long-Term Market Development Appendix Abbreviations and Terminologies Used in the Report References and Sources Regulatory Approvals and Clinical Development Milestones (2025–2026) List of Tables Market Size by Drug Class, Indication, Route of Administration, Distribution Channel, End User, and Region (2026–2032) Regional Market Breakdown by Segment Type (2026–2032) Country-Level Market Assessment Across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa Competitive Benchmarking of Leading Complement Inhibitor Companies Complement Inhibitor Product Portfolio and Regulatory Approval Analysis (2025–2026) Emerging Therapeutic Candidates and Clinical Pipeline Assessment (2026–2028) Technology Adoption Trends Across C5, C3, Factor B, C1s, C1q, and MASP-Targeting Therapies List of Figures Market Drivers, Challenges, Opportunities, and Restraints Regional Market Snapshot Competitive Landscape by Market Share Growth Strategies Adopted by Key Players Market Share by Drug Class, Indication, Route of Administration, Distribution Channel, and End User (2025 vs. 2032) Global Complement Inhibitors Ecosystem and Value Chain Analysis Complement Pathway Targets and Therapeutic Mechanism Overview Emerging Complement Inhibitor Pipeline and Development Timeline (2026–2028)